Sei Investments Co. Purchases 62,359 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Sei Investments Co. boosted its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 189.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 95,315 shares of the company's stock after purchasing an additional 62,359 shares during the quarter. Sei Investments Co. owned 0.18% of PROCEPT BioRobotics worth $7,675,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PRCT. Quantbot Technologies LP raised its position in shares of PROCEPT BioRobotics by 102.4% in the fourth quarter. Quantbot Technologies LP now owns 39,019 shares of the company's stock valued at $3,142,000 after buying an additional 19,742 shares in the last quarter. Teacher Retirement System of Texas bought a new position in PROCEPT BioRobotics during the 4th quarter worth $768,000. Xponance Inc. raised its holdings in PROCEPT BioRobotics by 14.2% in the 4th quarter. Xponance Inc. now owns 3,162 shares of the company's stock valued at $255,000 after acquiring an additional 394 shares in the last quarter. William Blair Investment Management LLC lifted its position in shares of PROCEPT BioRobotics by 12.6% during the 4th quarter. William Blair Investment Management LLC now owns 239,285 shares of the company's stock valued at $19,267,000 after acquiring an additional 26,783 shares during the period. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth $388,000. Institutional investors own 89.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Morgan Stanley dropped their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Truist Financial restated a "buy" rating and issued a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $94.29.

PROCEPT BioRobotics Price Performance

Shares of PRCT stock traded down $2.96 on Thursday, reaching $54.78. The company had a trading volume of 1,394,060 shares, compared to its average volume of 758,038. The stock has a market capitalization of $3.00 billion, a PE ratio of -28.09 and a beta of 1.05. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The business's 50-day moving average is $64.22 and its 200 day moving average is $77.19. PROCEPT BioRobotics Co. has a one year low of $45.56 and a one year high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock valued at $368,322 in the last 90 days. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).